HMGN2, a new anti-tumor effector molecule of CD8+ T cells

详细信息    查看全文

• 作者：Lin Su (1)
  Ankang Hu (1)
  Yang Luo (1)
  Wenjie Zhou (1)
  Ping Zhang (1)
  Yun Feng (1)
  
  1. State Key Laboratory of Oral Diseases ; West China College of Stomatology ; Sichuan University ; Chengdu ; Sichuan ; China
  
• 关键词：HMGN2 ; PMBC ; CD8+ T cells ; Antitumor activity ; Anti ; tumor effector molecule
• 刊名：Molecular Cancer
• 出版年：2014
• 出版时间：December 2014
• 年：2014
• 卷：13
• 期：1
• 全文大小：1,837 KB
• 参考文献：1. Edwards, KM, Davis, JE, Browne, KA, Sutton, VR, Trapani, JA (1999) Anti-viral strategies of cytotoxic T lymphocytes are manifested through a variety of granule-bound pathways of apoptosis induction. Immunol Cell Biol 77: pp. 76-89 CrossRef
  2. Anderson, DH, Sawaya, MR, Cascio, D, Ernst, W, Modlin, R, Krensky, A, Eisenberg, D (2003) Granulysin crystal structure and a structure-derived lytic mechanism. J Mol Biol 325: pp. 355-365 CrossRef
  3. Kumar, J, Okada, S, Clayberger, C, Krensky, AM (2001) Granulysin: a novel antimicrobial. Expert Opin Investig Drugs 10: pp. 321-329 CrossRef
  4. Hoesel, B, Schmid, JA (2013) The complexity of NF-魏B signaling in inflammation and cancer. Mol Cancer 12: pp. 86-97 CrossRef
  5. Beyaert, B, Beaugerie, L, Assche, GV, Brochez, L, Renauld, JC, Viguier, M, Cocquyt, V, Jerusalem, G, Machiels, JP, Prenen, H, Masson, P, Louis, E, Keyser, FD (2013) Cancer risk in immune-mediated inflammatory diseases (IMID). Mol Cancer 12: pp. 98-109 CrossRef
  6. Feng, Y, Huang, N, Wu, Q, Wang, BY (2005) HMGN2: a novel antimicrobial effector molecule of human mononuclear leukocytes?. J Leukoc Biol 78: pp. 1136-1141 CrossRef
  7. Bustin, M (1999) Regulation of DNA-dependent activities by the functional motifs of the high- mobility- group chromosomal proteins. Mol Cell Biol 19: pp. 5237-5246
  8. Yang, H, Antoine, DJ, Andersson, U, Tracey, KJ (2013) The many faces of HMGB1: molecular structure-functional activity in inflammation, apoptosis, and chemotaxis. J Leukoc Biol 93: pp. 865-873 CrossRef
  9. Harris, HE, Andersson, U, Pisetsky, DS (2012) HMGB1: a multifunctional alarmin driving autoimmune and inflammatory disease. Nat Rev Rheumatol 8: pp. 195-202 CrossRef
  10. Yanai, H, Ban, T, Wang, ZC, Choi, MK, Kawamura, T, Negishi, H, Nakasato, M, Lu, Y, Hangai, S, Koshiba, R, Savitsky, D, Ronfani, L, Akira, S, Bianchi, ME, Honda, K, Tamura, T, Kodama, T, Taniguchi, T (2009) HMGB proteins function as universal sentinels for nucleic-acid-mediated innate immune responses. Nature 462: pp. 99-103 CrossRef
  11. Gerlitz, G (2010) HMGNs, DNA repair and cancer. Biochim Biophys Acta 1799: pp. 80-85 CrossRef
  12. Birger, Y, Ito, Y, West, KL, Landsman, D, Bustin, M (2001) HMGN4, a newly discovered nucleosome- binding protein encoded by an intronless gene. DNA Cell Biol 20: pp. 257-264 CrossRef
  13. Bustin, M, Reeves, R (1996) High-mobility-group chromosomal proteins: architectural components that facilitate chromatin function. Prog Nucleic Acid Res Mol Biol 54: pp. 35-100 CrossRef
  14. West, KL, Ito, Y, Birger, Y, Postnikov, Y, Shirakawa, H, Bustin, M (2001) HMGN3a and HMGN3b, two protein isoforms with a tissue-specific expression pattern, expand the cellular repertoire of nucleosome-binding proteins. J Biol Chem 276: pp. 25959-25969 CrossRef
  15. Shirakawa, H, Landsman, D, Postnikov, YV, Bustin, M (2000) NBP-45, a novel nucleosomal binding protein with a tissue-specific and developmentally regulated expression. J Biol Chem 275: pp. 6368-6374 CrossRef
  16. Birger, Y, Catez, F, Furusawa, T, Lim, JH, Prymakowska-Bosak, M, West, KL, Postnikov, YV, Haines, DC, Bustin, M (2005) Increased tumorigenicity and sensitivity to ionizing radiation upon loss of chromosomal protein HMGN1. Cancer Res 65: pp. 6711-6718 CrossRef
  17. Rochman, M, Malicet, C, Bustin, M (2010) HMGN5/NSBP1: A new member of the HMGN protein family that affects chromatin structure and function. Biochim Biophys Acta 1799: pp. 86-92 CrossRef
  18. Li, DQ, Hou, YF, Wu, J, Chen, Y, Lu, JS, Di, GH, Ou, ZL, Shen, ZZ, Ding, J, Shao, ZM (2006) Gene expression profile analysis of an isogenic tumourmetastasis model reveals a functional role for oncogene AF1Q in breast cancer metastasis. Eur J Cancer 42: pp. 3274-3286 CrossRef
  19. Tang, WY, Newbold, R, Mardilovich, K, Jefferson, W, Cheng, RY, Medvedovic, M, Ho, SM (2008) Persistent hypomethylation in the promoter of nucleosomal binding protein 1 (Nsbp1) correlates with overexpression of Nsbp1 in mouse uteri neonatally exposed to diethylstilbestrol or genistein. Endocrinology 149: pp. 5922-5931 CrossRef
  20. Popescu, N, Landsman, D, Bustin, M (1990) Mapping the human gene coding for chromosomal protein HMG-17. Hum Genet 85: pp. 376-378 CrossRef
  21. Okamura, S, Ng, CC, Koyama, K, Takei, Y, Arakawa, H, Monden, M, Nakamura, Y (1999) Identification of seven genes regulated by wild-type p53 in a colon cancer cell line carrying a well-controlled wild-type p53 expression system. Oncol Res 11: pp. 281-285
  22. Bustin, M, Reisch, J, Einck, L, Klippel, JH (1982) Autoantibodies to nucleosomal proteins: antibodies to HMG-17 in autoimmune diseases. Science 215: pp. 1245-1247 CrossRef
  23. Porkka, K, Laakkonen, P, Hoffman, JA, Bernasconi, M, Ruoslahti, E (2002) A fragment of the HMGN2 protein homes to the nuclei of tumor cells and tumor endothelial cells in vivo. Proc Natl Acad Sci 99: pp. 7444-7449 CrossRef
  24. Hu, AK, Dong, XQ, Liu, XQ, Zhang, P, Zhang, YH, Su, N, Chen, QM, Feng, Y (2014) The nucleosome binding protein HMGN2 exhibits antitumor activity in oral squamous cell carcinoma. Oncol Lett 7: pp. 115-120
  25. Wei, DF, Zhang, P, Zhou, M, Feng, Y, Chen, QM (2014) HMGN2 protein inhibits the growth of infected T24 cells in vitro. J Cancer Res Ther 2: pp. 299-304
  
• 刊物主题：Cancer Research; Oncology;
• 出版者：BioMed Central
• ISSN：1476-4598

文摘

Background Cytolytic T lymphocytes (CTL) and natural killer (NK) cells have been implicated as important cells in antitumor responses. Our previous research has shown that high mobility group nucleosomal-binding domain 2 (HMGN2) could be released by IL-2 and PHA stimulated peripheral blood mononuclear cells (PBMCs) and also induced tumor cells apoptosis at low doses. In this study, we isolated and cultured PBMCs and CD8+ T cells to analyze the expression and antitumor effects of HMGN2. Methods PBMCs from healthy donors were isolated using Human Lymphocyte Separation tube. CD8+ T cells were separated from the PBMCs using MoFlo XDP high-speed flow cytometry sorter. Activation of PBMCs and CD8+ T cells were achieved by stimulating with Phytohemagglutinin (PHA) or tumor antigen. In addition, the methods of ELISA, intracellular staining, and fluorescence-labeling assays were used. Results PHA induced PBMCs to release high levels of HMGN2, and CD8+ T cells was the major cell population in PBMCs that release HMGN2 after PHA activation. Tumor antigen-activated CD8+ T cells also released high levels of HMGN2. Supernatants of tumor antigen-activated CD8+ T cells were able to kill tumor cells in a dose-dependent manner. This antitumor effect could be significantly blocked by using an anti-HMGN2 antibody. Fluorescence-labeling assays showed that the supernatant proteins of activated CD8+ T cells could be transported into tumor cells, and the transport visibly decreased after HMGN2 was depleted by anti-HMGN2 antibody. Conclusions These results suggest that HMGN2 is an anti-tumor effector molecule of CD8+ T cells.